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other countries. RESULTS: In terms of price cuts, the new PPRS is a continuation of 
previous schemes encompassing a 6–7% reduction. Price modulation and proﬁt con-
trols remained unchanged. However, ﬂexible pricing, which encourages companies to 
initially set lower prices to gain approval and increases prices as more evidence of 
effectiveness emerges, has been introduced. The most important difference concerns 
the introduction of PASs, which build on the idea of risk-sharing. Velcade and Lucentis 
provide useful examples of different approaches: the former deﬁning risk in terms of 
“patient response” (outcomes-based) and the latter according to treatment utilisation 
(ﬁnancial-based). Both schemes continue to be active. CONCLUSIONS: The new 
PPRS signiﬁes an important shift in the UK policy framework. The introduction of 
PASs raises issues about scheme implementation and how risk should be measured 
and tracked overtime. The progress of this initiative will shape the renegotiation 
of the next PPRS and the setting of future priorities. However, it is likely that 
“value-based pricing”—however deﬁned and understood—will continue to gain 
momentum.
PCN156
EFFECTS OF PHARMACEUTICAL INNOVATION AND DEMOGRAPHIC 
CHANGE ON THE GERMAN ONCOLOGY MARKET
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OBJECTIVES: Several studies forecasting health care spending predict continuously 
increasing expenses due to at least three different factors; ageing, technical progress, 
and increasing prices. The aim of this study is to identify the effects of inﬂuencing 
factors on the German oncology related expenditures on prescribed drugs (OREPD) 
considering predictor variables such as elderly (65 years and older) population 
(POP65), two pharmaceutical innovation proxies (product age [LC] and novelty 
[NEW]), parallel trade (PI), logarithmized prices (PRICE), and relevant health care 
reforms (REFORM) of oncology related ATC classes (ATC). METHODS: A Random 
Coefﬁcient Mixed Model is implemented to explore multivariate longitudinal/repeated 
observation data excluding between-drug variation from error, providing more efﬁ-
cient estimators by separating aging (changes over time within drugs) from cohort 
(differences between drugs at baseline) effects. RESULTS: The analyses including 
logarithmized German monthly prescription data for a 5 years period (2003–2007) 
covering all relevant ATC classes related to cancer treatment show highly signiﬁcant 
effects within a ﬁxed effects model for LC(0.0043,p  0.0001), NEW(1.6264,p  
0.0001), PI(2.1314,p  0.0001), and POP65(2.19E-7,p  0.0001). The random 
effect model also provides highly signiﬁcant results for the drug speciﬁc INTERCEPT 
(37.0127,p  0.0001), time-variant effects of REFORM(0.0005,p  0.0001), and 
PRICE(1.3300,p0.0001). CONCLUSIONS: The results show increasing oncology 
related prescriptions with increasing manufactures (respectively decreasing parallel 
importers) in the market and the longer the drugs are available in the market. It seems 
that prescriptions are inﬂuenced by a certain awareness and trust in new drugs. The 
newer the drug the less it’s prescribed which might be a consequence of risk adversity 
due to lacking experienced successful treatments. Decreasing prescriptions with 
increasing elderly population is somewhat counterintuitive but might be caused by 
multimorbidity and difﬁculties due to adverse effects of multiple prescriptions. The 
intercept indicates a high baseline and over time reforms are not successful in cost 
containment. Additionally, increasing prices lead to increasing oncology related 
prescriptions.
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OBJECTIVES: Studies have shown that the use of high-dose irinotecan in cancer 
therapy is associated with an increased risk for severe neutropenia in UGT1A1 7/7 
genotype patients. The aim of the present study was to evaluate cost-effectiveness of 
UGT1A1 genotyping prior to administration of high-dose irinotecan in second-line 
colorectal cancer treatment. METHODS: UGT1A1 genotyping with subsequent initial 
irinotecan dose reduction or a prophylactic use of G-CSF in UGT1A1 7/7 genotype 
patients was compared to standard therapy in a decision analysis. The effectiveness 
outcome was severe neutropenia occurrence and number of life-years gained. Cost-
effectiveness of UGT1A1 genotyping was calculated separately for patients with 
African, Asian and Caucasian origin due to different UGT1A1 7/7 genotype frequen-
cies. The analysis was performed from the USA health care payer perspective. 
RESULTS: UGT1A1 genotyping in combination with subsequent reduction of initial 
irinotecan dose for UGT1A1 7/7 genotype patients was cost-saving for the population 
of African and Caucasian origin. On the contrary, an incremental cost-effectiveness 
ratio was more than 6 mio USD per LYG for the population of Asian ancestry. Fur-
thermore, UGT1A1 genotyping with subsequent prophylactic use of granulocyte-
colony stimulating factors in UGT1A1 7/7 genotype patients resulted in incremental 
cost-effectiveness ratio above 3 mio USD per life-year gained for all population groups. 
CONCLUSIONS: The use of UGT1A1 genotyping prior to high-dose irinotecan 
therapy could represent a good value for money for certain patient groups.
PCN158
LUXEMBOURG LUNG CANCER PROJECT: POTENTIAL CLINICAL AND 
ECONOMIC IMPACT OF BIOMARKER DEVELOPMENT IN THE 
DIAGNOSIS AND TREATMENT OF SINGLE PULMONARY NODULES  
IN LUXEMBOURG
Carlson JJ1, Clarke L2, Berchem G3, Schlesser M3, Nelson J4, Ramsey SD4
1University of Washington, Seattle, WA, USA, 2Cornerstone Systems Northwest, Inc, 
Lynden, WA, USA, 3Centre Hospitalier de Luxembourg, Luxembourg City, Luxembourg, 
4Fred Hutchinson Cancer Research Center, Seattle, WA, USA
OBJECTIVES: As part of a program using economic evaluation to guide discovery 
efforts in personalized medicine, we evaluated the potential clinical and economic 
impact of biomarker-directed management of patients with single pulmonary nodules 
(SPN) versus current practice in Luxembourg. METHODS: We developed a decision 
analytic model from the payer perspective using data from Luxembourg and neighbor-
ing countries. Decision pathways were based on input from clinical experts and health 
services researchers. The model follows patients from SPN identiﬁcation to death 
comparing standard care (bronchoscopy, CT scans, and FDG PET scans) with bio-
marker-directed evaluation. Endpoints included lung cancers detected, false positive 
and negative tests, life expectancy, and related medical care costs. Threshold analyses 
were performed to assess levels of biomarker performance that would be cost-effective. 
RESULTS: Compared to standard care, biomarker-based management produced an 
average survival beneﬁt of 0.015 years and average cost savings of a1430, dominating 
standard care. The improved life expectancy was primarily the result of identifying 
and treating patients with malignant tumors earlier. The cost savings were primarily 
driven by avoiding costly diagnostic procedures (e.g. FDG PET). In sensitivity analysis, 
test characteristics for bronchoscopy and FDG PET had the largest impact on model 
results. At a sensitivity/speciﬁcity of 0.83/0.83, the biomarker-based strategy was no 
longer more effective than standard care. There was no simultaneous decrease in sen-
sitivity/speciﬁcity that made the biomarker based strategy more costly than standard 
care. Finally, the cost of the biomarker-based test could increase to a1530 with the 
strategy remaining less costly than standard care. CONCLUSIONS: Biomarkers have 
the potential to improve the management of patients diagnosed with SPN’s in Lux-
embourg. At a sensitivity/speciﬁcity of 0.95/0.95, biomarker-directed management 
could improve outcomes and reduce costs for the Luxembourg health system. Bio-
marker development efforts at this and other strategic points along the lung cancer 
treatment pathway are underway.
PCN159
TREND OF METASTASECTOMY AND CHEMO- AND BIOLOGIC 
THERAPY IN PATIENTS WITH METASTATIC COLORECTAL CANCER
Wang F1, Song X2, Zhao Z3, Barber B3, Long SR4
1Amgen Inc, Thousand Oaks, CA, USA, 2Thomson Reuters, Cambridge, MA, USA, 3Amgen, 
Inc., Thousand Oaks, CA, USA, 4Thomson Reuters, Hampden, ME, USA
OBJECTIVES: Metastasectomy in patients with metastatic colorectal cancer (mCRC) 
is the best option to achieve long-term survival and offers the only chance for cure. 
Increasing the number of resectable patients is therefore a medical treatment goal. This 
study examines the trend over time in metastasectomy and pre-surgery chemo- and 
biologic therapy in newly diagnosed mCRC patients. METHODS: Using a large, U.S. 
medical claims database from a national commercially-insured population, we identi-
ﬁed patients with newly diagnosed mCRC between 2001 and 2005. Metastasectomy 
rates by anatomic location were assessed for all mCRC patients during one year after 
mCRC diagnosis. Chemotherapy and/or biological therapy within 90 days prior to 
the date of metastasectomy was evaluated. RESULTS: A total of 1785 newly diag-
nosed mCRC patients were identiﬁed; of which 327 patients (18.3%) received metas-
tasectomy within one year after mCRC diagnosis. This included 70 patients (3.9%) 
who were not initially resected but had metastasectomy following chemo- and/or 
biologic therapy. From 2001 to 2005, the most common surgery site was the liver 
(ranged 13.9%–16.7%), followed by the lung (2.3% to 4.9%) and pelvic resection 
(0.0%–0.5%). The percentage of patients who were not initially resected and had 
metastasectomy after receiving chemo- and/or biologic therapy increased from 2.9% 
in 2001 to 5.6% in 2005. Among patients who received pre-surgery chemo- and/or 
biologic therapy, the percentage of receiving biologic therapy increased rapidly in 
2004–2005 from 35.0% to 77.3%. CONCLUSIONS: The proportion of patients with 
mCRC undergoing metastasectomy increased over time and the percentage of patients 
who were not initially resected and had metastasectomy after receiving chemo- and/or 
biologic therapy almost doubled during the study period.
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OBJECTIVES: Modern targeted anticancer therapy introduces powerful treatment 
modality in cancer care. However, due to its cost the overall number of administra-
tions has to be monitored and prospectively planned. The objective of this work is to 
design, apply and verify a multi-component statistical model that employs data from 
population records, clinical registries and data provided by an expert panel to predict 
the number of cancer patients who would be probably treated with targeted therapy 
in the following years. METHODS: Computations are primarily based on data from 
the Czech National Cancer Registry, which covers the entire population since 1977. 
The modelling process has two steps. In the ﬁrst step, number of potentially treated 
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cancer patients irrespective of drug is identiﬁed. The estimate combines the prediction 
of number of newly diagnosed and treated patients with the prediction of number of 
patients who were diagnosed previously and would probably be treated in a given 
year due to a relapse or progression of the primary malignant disease. In the second 
step patients are localised to individual drugs according to treatment scheme provided 
by the panel of experts, adjusted using information from clinical registries. RESULTS: 
The model currently provides predictions of potentially treated patients with quanti-
ﬁed uncertainties. Regarding the most common targeted anticancer therapies, follow-
ing numbers of treated patients are estimated for 2009 (90% CI): 836 (725; 948) 
patients receiving trastuzumab for breast cancer, 1283 (859; 1705) patients receiving 
bevacizumab for colorectal cancer, 300 (151; 449) patients receiving cetuximab for 
colorectal cancer and 514 (469; 557) patients receiving erlotinib for non-small cell 
lung carcinoma. CONCLUSIONS: Presented model allows us to predict the number 
of patients requiring targeted anticancer therapy in the years to come. Final outcome 
is used by decision makers for planning of health care expenses in the Czech 
Republic.
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OBJECTIVES: The aim of this analysis is to compare the reimbursement rates for 
administration costs of triplet therapy bevacizumab-cisplatin-gemcitabine (BCG) 
versus doublet therapy cisplatin-pemetrexed (CP) for mNSCLC patients in France and 
German health care systems. METHODS: A systematic literature search performed 
in Medline, Embase, Cochrane, and Centre of Reviews and Dissemination databases 
identiﬁed 578 publications of anticancer agents. In addition, an evaluation of national 
reimbursement tariffs in both inpatient and outpatient settings was performed. 
Country-speciﬁc reimbursement structures were veriﬁed by two in-depth semi-struc-
tured expert oncologist interviews in each country. RESULTS: No publication includ-
ing reimbursement tariffs for the administration of anticancer agents was identiﬁed 
during the systematic literature review. The evaluation of the national reimbursement 
tariffs showed signiﬁcant costs for the administration service. The French GHS # 9606 
“Chimiothérapie pour tumeur, en séances” is the reimbursement tariff of one inpatient 
chemotherapy session valued at a385.77 (public sector). The chemotherapy home 
infusion tariff code “chemotherapy, intravenous treatment” is valued at a374.16 
irrespective of the number of injections administered. In Germany the inpatient 
 reimbursement tariff G-DRG # E71B “Neubildung der Atmungsorgane” refers to the 
indication “neoplasm” with a cost of a1.671 for an inpatient visit and a610.40 for 
an outpatient visit. In both reimbursement systems these are ﬂat rates irrespective of 
the number of chemotherapeutic drugs administered. CONCLUSIONS: When com-
paring the reimbursement for administrations of anticancer treatment combinations 
in France and Germany administration costs are unaffected by single, double or triple 
chemotherapy combinations. Therefore there is no difference in the cost of reimburse-
ment for administration for BCG versus CP.
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OBJECTIVES: Despite implementation of radical cost control measures, pharmaceuti-
cal expenditure is expected to keep increasing due to highly innovative, expensive 
drugs, including immunotherapeutics. The objective of this study was to understand 
how different markets are responding to cost containment pressures, using a compare-
and-contrast approach of reimbursement decisions for three recently approved treat-
ments for metastatic renal cell carcinoma (mRCC). Based on the ﬁndings we propose 
fundamentals to build acceptable reimbursement strategies for AI, including cancer 
vaccines. METHODS: We examined commonalities and differences of three drugs 
for mRCC, assessing drug costs, health technology assessments (HTA), and reimburse-
ment decisions across 7 countries with similar pharmaceutical funding schemes 
(Canada, France, Germany, Italy, Spain, Sweden, and the UK). In each of the 7 coun-
tries primary reimbursement criteria for these drugs were identiﬁed, local HTAs were 
reviewed, and speciﬁc qualitative research with local payers and experts was con-
ducted. For country comparisons, drug treatment costs were calculated from a payer 
perspective (6 weeks therapy). RESULTS: Treatment cost differences in the seven 
countries were minimal and mostly related to exchange rates indicating that, for 
innovative drugs, price convergence has been achieved in these countries. More than 
70% of the total HTA evaluations conducted involved immunotherapeutics. Only the 
SMC assessment recommended against the use of the 3 studied drugs. Most countries 
apply or are studying some type of risk sharing scheme or access/restriction program 
for forthcoming drugs. CONCLUSIONS: Most payers accept high priced drugs; 
however, they certainly restrict patient access or set up different types of agreements 
with suppliers to be able to maintain budget control. Current reimbursement schemes 
in the countries studied will need to evolve according to similar parameters in order 
to give access to highly complex therapies as AI. In each country, the feasibility of 
implementing processes to track drug use, cost and outcomes will determine how these 
reimbursement schemes develop.
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OBJECTIVES: Colorectal cancer (CRC) is the third leading cause of cancer mortality 
in the US with disparities in risk between rural and urban patients. The aim of the 
study was to: 1) describe the characteristics of hospital admissions, 2) compare the 
length of stay and in-hospital deaths in rural and urban West Virginia residents with 
a primary diagnosis of CRC. METHODS: Data from the Health Care Cost and 
 Utilization Project, State Inpatient Database for the years 2003, 2005, 2006 and 
2007 were used to perform analyses of all discharges with a primary diagnosis of 
CRC. Chi square tests compared categorical descriptive statistics between rural and 
urban cases. One-way ANOVA compared mean length of stay based on rural-urban 
category. RESULTS: Admissions for CRC as a primary diagnosis decreased constantly 
from 882 in 2003 to 787 in 2007. In-hospital deaths rose steadily from 5.1% in 2003 
to 7% in 2006, but fell to 5.7% in 2007. Mean ages ranged between 69.6 years and 
70.3 years and percentage of female admissions ranged between 53.1% and 55.2% 
over the four years. A greater proportion of patients from large metros (17.4%) died 
in-hospital compared to small metros (7.0%), micropolitan (4.4%) and rural (5.2%) 
areas (p  0.001). Leading primary payer was Medicare for all four locations. Rural 
patients had the shortest mean length of stay (9.0 days). The mean length of stay dif-
fered signiﬁcantly between rural (9.0 days) and micropolitan (10.0 days) patients. 
CONCLUSIONS: Colorectal cancer provides a signiﬁcant burden to the health care 
system in West Virginia. Unlike previously reported in certain other states and coun-
tries, a greater proportion of urban residents in West Virginia are dying in-hospital 
due to CRC. The reasons for these disparities go beyond demographic differences 
between rural-urban residents and need to be explored.
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RECEIVING MODERATELY OR HIGHLY EMETOGENIC (MOHE) 
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OBJECTIVES: Chemotherapy-induced vomiting (CIV) is a frequent side effect of 
cancer treatment, with debilitating symptoms and negative effects on quality of life. 
CIV may be acute (within 24 hours of chemotherapy) or delayed (up to 7 days later). 
Different doses of PAL are available but the ideal one is still unknown. A recent meta-
analysis demonstrated that PAL is more effective than other serotonin inhibitors in 
preventing nausea and CIV in patients receiving MoHE chemotherapy. We aimed to 
perform a SR and MA of all randomized controlled trials (RCT) comparing PAL 
0.25 mg (or 0.3–1 mcg/kg) to PAL 0.75 mg (or 10 mcg/kg) as single intravenous doses 
in this setting of patients. METHODS: We searched several databases: MEDLINE, 
EMBASE, LILACS, and CENTRAL. The primary endpoints were the incidence of 
acute and delayed vomiting. The side effects of each treatment were analyzed. A sub-
group analysis was planned and performed to evaluate the inﬂuence of the use of 
corticosteroids. The results of individual studies were pooled in MA, using the 
RevMan 5.1 software. The results are expressed as Risk Ratio (RR) and the corre-
spondent 95% Conﬁdence Interval (CI). RESULTS: Eight studies with 1674 patients 
were included. There was no difference between the efﬁcacy of the evaluated doses in 
preventing either acute (RR  1.04; CI  95%  0.91 to 1.18; p  0.60) or delayed 
vomiting (RR  1.01; CI95%  0.90 to 1.13; p  0.89). There were no differences in 
side effects either: headache (RR  0.88; CI95%  0.64 to 1.20; p  0.41), dizziness 
(RR  1.20; CI95%  0.33 to 4.35; p  0.78), constipation (RR  0.67; CI95%  
0.42 to 1.06; p  0.09) or diarrhea (RR  1.51; CI95%  0.43 to 5.31; p  0.52). The 
subgroup analysis found that the addition of corticosteroids had no impact on the 
efﬁcacy of PAL. CONCLUSIONS: Both doses of PAL have equal efﬁcacy and safety 
proﬁle in preventing CIV in patients receiving MoHE chemotherapy. The choice of 
scheme, in this situation, must be the least costly one.
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OBJECTIVES: To perform a review of the published meta-analyses, systematic reviews 
and health technology assessments reports (HTAR) which evaluated the use of ritux-
imab for the treatment of non-Hodgkin lymphoma (NHL) regarding its beneﬁts, safety 
proﬁle and cost-effectiveness. METHODS: A search of MEDLINE, Lilacs, Cochrane 
library, Web of science and INAHTA websites from 1990 to 2009 was conducted. 
The following MESH terms were used: “Meta-Analysis”, “Systematic Reviews”, 
“Lymphoma, Non-Hodgkin”, “Lymphoma, Large B-Cell, Diffuse” and “rituximab”. 
Included studies were those which evaluated the use of rituximab alone and/or in 
combination with other therapies in ﬁrst line, second line and maintenance therapy 
for naive, refractory patients or relapsed disease in different patient characteristics. 
